Rhenman & Partners Asset Management Ab Raised Its Esperion Therapeutics INC (ESPR) Stake

April 17, 2018 - By Bradley Stiles

Investors sentiment decreased to 1.33 in Q4 2017. Its down 0.34, from 1.67 in 2017Q3. It turned negative, as 19 investors sold ESPR shares while 39 reduced holdings. 33 funds opened positions while 44 raised stakes. 22.69 million shares or 0.18% less from 22.73 million shares in 2017Q3 were reported. Parallax Volatility Advisers LP reported 2,562 shares. Dimensional Fund Advsr L P, Texas-based fund reported 86,676 shares. Columbus Circle Investors reported 87,029 shares. 5,191 were reported by Two Sigma Secs Limited Co. Pinnacle Associate owns 0.83% invested in Esperion Therapeutics, Inc. (NASDAQ:ESPR) for 659,803 shares. New Jersey-based State Of New Jersey Common Pension Fund D has invested 0.01% in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Caisse De Depot Et Placement Du Quebec holds 0.04% or 250,000 shares. Quantbot Techs Ltd Partnership holds 354 shares or 0% of its portfolio. Moreover, Great West Life Assurance Company Can has 0% invested in Esperion Therapeutics, Inc. (NASDAQ:ESPR) for 3,128 shares. 30 are owned by Toth Advisory Corporation. Iguana Healthcare Mngmt Limited Liability Company invested in 165,000 shares or 7.08% of the stock. Natixis accumulated 10,077 shares. American Gru Incorporated Inc holds 0% in Esperion Therapeutics, Inc. (NASDAQ:ESPR) or 11,430 shares. Price T Rowe Md, Maryland-based fund reported 190,087 shares. Ontario Teachers Pension Plan Board reported 24,832 shares stake.

Rhenman & Partners Asset Management Ab increased its stake in Esperion Therapeutics Inc (ESPR) by 24% based on its latest 2017Q4 regulatory filing with the SEC. Rhenman & Partners Asset Management Ab bought 74,823 shares as the company’s stock rose 22.41% while stock markets declined. The institutional investor held 386,626 shares of the health care company at the end of 2017Q4, valued at $25.46 million, up from 311,803 at the end of the previous reported quarter. Rhenman & Partners Asset Management Ab who had been investing in Esperion Therapeutics Inc for a number of months, seems to be bullish on the $2.06 billion market cap company. The stock increased 4.43% or $3.3 during the last trading session, reaching $77.79. About 294,555 shares traded. Esperion Therapeutics, Inc. (NASDAQ:ESPR) has risen 89.86% since April 17, 2017 and is uptrending. It has outperformed by 78.31% the S&P500.

Rhenman & Partners Asset Management Ab, which manages about $740.07 million US Long portfolio, decreased its stake in Livanova Plc by 42,000 shares to 53,000 shares, valued at $4.24 million in 2017Q4, according to the filing. It also reduced its holding in Abiomed Inc (NASDAQ:ABMD) by 53,748 shares in the quarter, leaving it with 86,490 shares, and cut its stake in Medtronic Plc (NYSE:MDT).

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Ratings Coverage

Among 11 analysts covering Esperion (NASDAQ:ESPR), 7 have Buy rating, 0 Sell and 4 Hold. Therefore 64% are positive. Esperion had 17 analyst reports since October 18, 2017 according to SRatingsIntel. The rating was maintained by Stifel Nicolaus with “Buy” on Monday, January 15. On Wednesday, January 17 the stock rating was maintained by UBS with “Buy”. The company was maintained on Wednesday, November 22 by Northland Capital. JP Morgan maintained Esperion Therapeutics, Inc. (NASDAQ:ESPR) on Wednesday, February 21 with “Neutral” rating. Jefferies maintained the shares of ESPR in report on Monday, March 19 with “Buy” rating. As per Wednesday, March 7, the company rating was maintained by Cowen & Co. On Wednesday, October 18 the stock rating was maintained by Cowen & Co with “Buy”. The firm has “Buy” rating by Needham given on Thursday, December 14. The firm earned “Buy” rating on Wednesday, February 21 by Needham. The stock of Esperion Therapeutics, Inc. (NASDAQ:ESPR) has “Buy” rating given on Tuesday, March 27 by Cowen & Co.

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: